TJPC(SH:600488) Zheng Quan Zhi Xing·2025-07-15 16:06Core Viewpoint - The legal opinion letter from Changshi Law Firm confirms that the 2025 Second Extraordinary General Meeting of Tianjin Pharmaceutical Co., Ltd. was convened and conducted in accordance with relevant laws, regulations, and the company's articles of association [1][8]. Group 1: Meeting Procedures - The meeting was convened based on a resolution from the 17th meeting of the 9th Board of Directors held on June 25, 2025, and the notice was published on June 26, 2025 [3][4]. - The meeting was held on July 15, 2025, at the specified location, and the actual time and place matched the notice [4][6]. - A network voting platform was provided for shareholders, allowing them to vote during specified times [4][7]. Group 2: Attendance and Qualifications - A total of 8 shareholders and their proxies attended the meeting, representing 9,243,482 shares, which is 0.8466% of the total voting shares [4][5]. - Additionally, 293 shareholders participated via the network voting system, representing 36,877,352 shares, or 3.3377% of the total voting shares [5]. - The qualifications of all attendees, including the convenor, were verified to be in compliance with relevant laws and the company's articles of association [5][6]. Group 3: Voting Results - The first agenda item regarding the mortgage application for a loan by a controlling subsidiary was approved with 43,376,634 votes in favor (94.0499%), 1,999,800 votes against (4.3360%), and 744,400 abstentions (1.6141%) [6][8]. - The voting procedures and results were confirmed to be valid and in accordance with legal requirements and the company's articles of association [8].